In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals

References

• Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11: 93–100
   PubMed Web of Science ®Google Scholar
• Livingstone D, Gill MJ, Wise R. Mechanisms of resistance to carbapenems. J Antimicrob Chemother 1995; 35: 1–5
   PubMed Web of Science ®Google Scholar
• Livermore DM, Woodford N. Carbapenemases: a problem in waiting?. Curr Opin Microbiol 2000; 3: 489–95
   PubMed Web of Science ®Google Scholar
• Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the Quiet before the Storm?. Clin Microbiol Rev 2005; 18: 306–25
   PubMed Web of Science ®Google Scholar
• Villar HE, Danel F, Livermore DM. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams. J Antimicrob Chemother 1997; 40: 365–70
   PubMed Web of Science ®Google Scholar
• Neuwirth C, Siebor E, Duez JM, Pechinot A, Kazmierczak A. Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. J Antimicrob Chemother 1995; 36: 35–42
   PubMedGoogle Scholar
• Bornet C, Davin-Regli A, Bosi C, Pages JM, Bollet C. Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol 2000; 38: 1048–52
   PubMed Web of Science ®Google Scholar
• Lee EH, Nicolas MH, Kitzis MD, Pialoux G, Collatz E, Gutmann L. Association of 2 resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem. Antimicrob Agents Chemother 1991; 35: 1093–8
   PubMed Web of Science ®Google Scholar
• Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47: 247–50
   PubMed Web of Science ®Google Scholar
• Nikaido H. Antibiotic resistance caused by Gram-negative multidrug efflux pumps. Clin Infect Dis 1998; 27(Suppl 1)32–41
   PubMed Web of Science ®Google Scholar
• Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other non-fermentative gram-negative bacteria. Clin Infect Dis 1998; 27(Suppl 1)93–9
   PubMed Web of Science ®Google Scholar
• Hanberger H, Nilsson LE, Claesson B, Karnell A, Larsson P, Rylander M, et al. New species-related MIC breakpoints for early detection of development of resistance among Gram-negative bacteria in Swedish intensive care units. J Antimicrob Chemother 1999; 44: 611–9
   PubMedGoogle Scholar
• Mutnick AH, Turner PJ, Jones RN. Emerging antimicrobial resistance among Proteus mirabilis in Europe: report from the MYSTIC Program (1997–2001). Meropenem Yearly Susceptibility Test Information Collection. J Chemother 2002; 14: 253–8
   PubMed Web of Science ®Google Scholar
• Steward CD, Mohammed JM, Swenson JM, Stocker SA, Williams PP, Gaynes RP, et al. Antimicrobial susceptibility testing of carbapenems: multicentre validity testing and accuracy levels of 5 antimicrobial test methods for detecting resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolates. J Clin Microbiol 2003; 41: 351–8
   PubMed Web of Science ®Google Scholar
• Hanberger H, Diekema D, Fluit A, Jones R, Struelens M, Spencer R, et al. Surveillance of antibiotic resistance in European ICUs. J Hosp Infect 2001; 48: 161–76
   PubMed Web of Science ®Google Scholar
• Fluit AC, Verhoef J, Schmitz FJ., European SENTRY Participants. Frequency of isolation and antimicrobial resistance of Gram-negative and Gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Programme 1997–1998. Eur J Clin Microbiol Infect Dis 2001; 20: 617–25
   PubMed Web of Science ®Google Scholar
• Livermore DM, Carter MW, Bagel S, Wiedemann B, Baquero F, Loza E, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001; 45: 1860–7
   PubMed Web of Science ®Google Scholar
• Goossens H, MYSTIC Study Group (Europe). MYSTIC programme: summary of European data from 1997to 2000. Diagn Microbiol Infect Dis 1997; 41: 183–9
   Google Scholar
• Fuchs PC, Barry AL, Brown SD. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests. J Antimicrob Chemother 1999; 43: 703–6
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centres. Antimicrob Agents Chemother 2001; 45: 1915–8
   PubMed Web of Science ®Google Scholar
• Wexler H. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004; 53 (Suppl): 11–21
   Google Scholar
• Livermore DM, Mushtaq S, Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 2005; 55: 306–11
   PubMed Web of Science ®Google Scholar
• Friedland IR, Isaacs R, Mixson LA, Motyl M, Woods GL. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagn Microbiol Infect Dis 2002; 43: 61–4
   PubMedGoogle Scholar
• Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331–44
   PubMed Web of Science ®Google Scholar
• Kohler J, Dorso KL, Young K, Hammond GG, Rosen H, Kropp H, et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother 1999; 43: 1170–6
   PubMed Web of Science ®Google Scholar